Stock Analysis on Net

Medtronic PLC (NYSE:MDT)

$24.99

Analysis of Solvency Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Solvency Ratios (Summary)

Medtronic PLC, solvency ratios (quarterly data)

Microsoft Excel
Oct 24, 2025 Jul 25, 2025 Apr 25, 2025 Jan 24, 2025 Oct 25, 2024 Jul 26, 2024 Apr 26, 2024 Jan 26, 2024 Oct 27, 2023 Jul 28, 2023 Apr 28, 2023 Jan 27, 2023 Oct 28, 2022 Jul 29, 2022 Apr 29, 2022 Jan 28, 2022 Oct 29, 2021 Jul 30, 2021 Apr 30, 2021 Jan 29, 2021 Oct 30, 2020 Jul 31, 2020
Debt Ratios
Debt to equity
Debt to capital
Debt to assets
Financial leverage
Coverage Ratios
Interest coverage

Based on: 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).


The analysis of the financial ratios over the presented periods reveals several notable trends and patterns regarding the company's leverage and ability to cover interest expenses.

Debt to Equity Ratio
This ratio exhibited fluctuations over the observed timeline. Initially, it showed a slight increase from 0.57 to 0.6 in late 2020 and early 2021, followed by a gradual decline to around 0.44 by mid-2022. After reaching this low, the ratio began to rise again, ultimately returning to 0.6 by late 2025. This pattern suggests periods of both increased and decreased reliance on debt financing relative to equity, indicating variability in capital structure strategy.
Debt to Capital Ratio
The debt to capital ratio demonstrated a modest downward trend during the first half of the timeline, decreasing from 0.36 to approximately 0.31. Starting mid-2022, it began a gradual climb back to 0.37 by the end of the period. The generally narrow range of values indicates that the company maintained a relatively stable balance between debt and overall capital, with minor shifts signaling cautious adjustments in financing sources.
Debt to Assets Ratio
This ratio followed a pattern closely aligned with the debt to capital ratio, starting at 0.31, decreasing to about 0.26 by mid-2022, then increasing back to 0.32 toward the end of the observed period. The relatively stable ratio suggests a consistent proportion of debt financing relative to total assets, with temporary decreases possibly reflecting asset growth or debt reduction strategies.
Financial Leverage Ratio
The financial leverage ratio decreased from 1.87 to a low of approximately 1.71 in mid-2022, consistent with earlier trends indicating reduced reliance on debt or increased equity. Afterward, it rose to about 1.91 by late 2025. This movement corroborates the fluctuations observed in debt-related ratios and indicates periodic shifts in the structure of the company's financing and asset base.
Interest Coverage Ratio
This ratio showed considerable variability with an initial drop from 6.6 in mid-2020 to 3.68 by early 2021, signaling a reduced capacity to cover interest expenses during that period. Subsequently, there was a marked improvement, peaking above 11 in late 2021 and early 2022, reflecting enhanced earnings relative to interest obligations. Since then, the ratio gradually declined but remained relatively strong, fluctuating around 7.5 to 9.0 toward the end of the period. This indicates sustained ability to meet interest payments, albeit with some volatility over time.

Debt Ratios


Coverage Ratios


Debt to Equity

Medtronic PLC, debt to equity calculation (quarterly data)

Microsoft Excel
Oct 24, 2025 Jul 25, 2025 Apr 25, 2025 Jan 24, 2025 Oct 25, 2024 Jul 26, 2024 Apr 26, 2024 Jan 26, 2024 Oct 27, 2023 Jul 28, 2023 Apr 28, 2023 Jan 27, 2023 Oct 28, 2022 Jul 29, 2022 Apr 29, 2022 Jan 28, 2022 Oct 29, 2021 Jul 30, 2021 Apr 30, 2021 Jan 29, 2021 Oct 30, 2020 Jul 31, 2020
Selected Financial Data (US$ in millions)
Current debt obligations
Long-term debt
Total debt
 
Shareholders’ equity
Solvency Ratio
Debt to equity1
Benchmarks
Debt to Equity, Competitors2
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).

1 Q2 2026 Calculation
Debt to equity = Total debt ÷ Shareholders’ equity
= ÷ =

2 Click competitor name to see calculations.


The analysis of the quarterly financial data reveals several noteworthy trends regarding the company's debt, equity, and leverage ratios over the observed period.

Total Debt
Total debt exhibited a fluctuating yet generally resilient pattern. Starting at approximately 28.7 billion USD, it experienced an initial increase toward late 2020, reaching just over 30 billion USD. Subsequently, it trended downward through mid-2022, falling to around 23.2 billion USD by July 2022. Thereafter, debt levels increased again, climbing to roughly 29.1 billion USD by the latest quarter. This pattern suggests periods of debt reduction followed by subsequent borrowing, indicating active management of leverage possibly responding to strategic or market conditions.
Shareholders’ Equity
Shareholders’ equity remained relatively stable throughout the period, beginning near 50.3 billion USD and fluctuating modestly around this level. After slight increases into early 2022, equity values showed a mild decline in late 2023 and 2024, reaching a low point below 48 billion USD, before stabilizing again near 48.7 billion USD by the end of the dataset. The limited variability indicates consistent equity maintenance without significant equity issuances or repurchases severely impacting book value.
Debt to Equity Ratio
The debt to equity ratio reflects these movements in debt and equity, ranging from a low of approximately 0.44 to highs nearing 0.60. The ratio decreased during the period when total debt was reduced and equity relatively stable, suggesting improved leverage positions early to mid-period. However, toward the latter quarters, this ratio rose again above 0.58, pointing to higher leverage. This cyclical pattern of leverage indicates the company’s ongoing balancing act between debt financing and equity base, maintaining a moderate risk profile but with varying capital structure preferences over time.

In summary, the company managed its capital structure dynamically, reducing debt during certain intervals to strengthen leverage metrics, but subsequently increasing borrowing, perhaps to finance growth or operational needs. Equity levels were fairly consistent without large disruptions. The leverage ratio has alternated in a moderate range, indicating a controlled approach to financial risk management across the quarters analyzed.


Debt to Capital

Medtronic PLC, debt to capital calculation (quarterly data)

Microsoft Excel
Oct 24, 2025 Jul 25, 2025 Apr 25, 2025 Jan 24, 2025 Oct 25, 2024 Jul 26, 2024 Apr 26, 2024 Jan 26, 2024 Oct 27, 2023 Jul 28, 2023 Apr 28, 2023 Jan 27, 2023 Oct 28, 2022 Jul 29, 2022 Apr 29, 2022 Jan 28, 2022 Oct 29, 2021 Jul 30, 2021 Apr 30, 2021 Jan 29, 2021 Oct 30, 2020 Jul 31, 2020
Selected Financial Data (US$ in millions)
Current debt obligations
Long-term debt
Total debt
Shareholders’ equity
Total capital
Solvency Ratio
Debt to capital1
Benchmarks
Debt to Capital, Competitors2
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).

1 Q2 2026 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =

2 Click competitor name to see calculations.


Total Debt
The total debt exhibits a fluctuating trend over the observed periods. Starting at approximately $28.7 billion, it initially increased to about $30 billion by late 2020 and early 2021. This was followed by a steady decline through most of 2021 and early 2022, reaching a low around $23.2 billion by mid-2022. Subsequently, the debt level increased again, peaking near $28.1 billion in early 2023. From this point onward, the total debt showed moderate fluctuations but generally remained in the range of $24 billion to $29 billion through late 2025, with a slight upward trend toward the end of the period.
Total Capital
Total capital remained relatively stable over the period, with minor variations. The value started just under $79 billion and experienced small declines and recoveries throughout. Notably, capital dipped during some mid-period quarters, particularly in early to mid-2023, but recovered slightly later, ending close to $77.8 billion by late 2025. Overall, the total capital exhibited limited volatility, maintaining a consistent base despite variations in debt levels.
Debt to Capital Ratio
The debt to capital ratio demonstrated a pattern closely tied to the changes in total debt and capital. Initially, the ratio hovered around 0.36-0.37, declining gradually to a low near 0.31 by mid-2022, reflecting the reduction in debt. After this period, the ratio rose again, reaching around 0.35 by early 2023 before stabilizing in the range of 0.32 to 0.33 for several quarters. Toward the final periods, a discernible increase is seen with the ratio again reaching approximately 0.37 by late 2025. This indicates a cycle of leverage reduction followed by a moderate increase, suggesting fluctuating capital structure dynamics but without extreme shifts.
Summary of Financial Leverage Trends
Overall, the company’s leverage experienced moderate variability within a relatively narrow range throughout the periods analyzed. Periods of debt reduction were generally mirrored by decreases in the debt to capital ratio, indicating efforts to manage financial leverage. However, subsequent increases in debt towards the later periods drove the ratio back up, reflecting a rise in indebtedness relative to total capital. The stability of total capital during these fluctuations suggests that the firm’s equity base remained steady, with changes in leverage primarily driven by debt movements rather than equity adjustments.

Debt to Assets

Medtronic PLC, debt to assets calculation (quarterly data)

Microsoft Excel
Oct 24, 2025 Jul 25, 2025 Apr 25, 2025 Jan 24, 2025 Oct 25, 2024 Jul 26, 2024 Apr 26, 2024 Jan 26, 2024 Oct 27, 2023 Jul 28, 2023 Apr 28, 2023 Jan 27, 2023 Oct 28, 2022 Jul 29, 2022 Apr 29, 2022 Jan 28, 2022 Oct 29, 2021 Jul 30, 2021 Apr 30, 2021 Jan 29, 2021 Oct 30, 2020 Jul 31, 2020
Selected Financial Data (US$ in millions)
Current debt obligations
Long-term debt
Total debt
 
Total assets
Solvency Ratio
Debt to assets1
Benchmarks
Debt to Assets, Competitors2
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).

1 Q2 2026 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =

2 Click competitor name to see calculations.


Total Debt
The total debt level exhibits some fluctuations over the observed periods. Starting at approximately $28.7 billion, the debt initially shows a modest increase reaching around $30 billion early on. Subsequently, there is a general declining trend in total debt until the midpoint of the timeline, hitting a low near $23 billion. However, debt levels then rise again, fluctuating slightly around $25 billion before increasing back towards the initial range, ending near $29.1 billion. This pattern indicates periods of both debt reduction and accumulation, with a notable dip followed by a recovery towards previous levels.
Total Assets
Total assets remain relatively stable throughout the periods, generally ranging between $89.9 billion and $94.1 billion. There is a small downward trend noticeable in the earlier half of the timeline, with asset values reducing from nearly $94 billion down to just below $90 billion. In later periods, asset values slightly recover and fluctuate but remain within a narrow band, ending at approximately $91.3 billion. This stability suggests the company maintains a consistent asset base despite fluctuations in debt.
Debt to Assets Ratio
The debt to assets ratio indicates changes in financial leverage and shows a pattern consistent with the fluctuations observed in debt and assets. Initially stable at about 0.31, the ratio declines to a low of around 0.26, corresponding with the period of decreasing debt and relatively stable assets. Following this, the ratio increases again, peaking eventually at around 0.32 near the end of the observed periods. This suggests an overall increase in leverage back to slightly above initial levels, driven primarily by the rebound in total debt relative to assets.
Overall Insights
The data exhibits a cyclical movement in debt, with a period of reduction followed by renewed increases, while assets remain comparatively steady. The debt to asset ratio follows this trend, reflecting changing leverage levels. The recent upward movement in debt relative to assets may warrant monitoring, as it implies a modest increase in financial risk. However, the relative stability in total assets suggests the company's asset base remains solid, potentially mitigating some concerns about leverage increases.

Financial Leverage

Medtronic PLC, financial leverage calculation (quarterly data)

Microsoft Excel
Oct 24, 2025 Jul 25, 2025 Apr 25, 2025 Jan 24, 2025 Oct 25, 2024 Jul 26, 2024 Apr 26, 2024 Jan 26, 2024 Oct 27, 2023 Jul 28, 2023 Apr 28, 2023 Jan 27, 2023 Oct 28, 2022 Jul 29, 2022 Apr 29, 2022 Jan 28, 2022 Oct 29, 2021 Jul 30, 2021 Apr 30, 2021 Jan 29, 2021 Oct 30, 2020 Jul 31, 2020
Selected Financial Data (US$ in millions)
Total assets
Shareholders’ equity
Solvency Ratio
Financial leverage1
Benchmarks
Financial Leverage, Competitors2
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).

1 Q2 2026 Calculation
Financial leverage = Total assets ÷ Shareholders’ equity
= ÷ =

2 Click competitor name to see calculations.


The analysis of the quarterly financial data reveals several important trends relating to the company’s asset base, equity position, and leverage ratios over the observed periods.

Total Assets

Total assets display moderate fluctuations throughout the timeline. Starting at approximately $93.9 billion, the asset base shows a tendency to slightly decline across the earlier periods, reaching a lower point near $89.9 billion in mid-2022 and again in early 2024. Despite some recovery attempts later, the overall level remains relatively stable but does not exhibit a clear upward growth trend. This suggests a relatively stable but non-expansive capital structure across these quarters.

Shareholders’ Equity

Shareholders’ equity remains fairly steady in the early quarters, maintaining a level around $50 billion to $52 billion. However, from mid-2023 onward, a downtrend emerges with a gradual decline culminating in a dip below $48 billion by early 2025. Some volatility is observed, but the overall movement suggests a weakening equity base, which may raise considerations regarding retained earnings, dividend policies, or other equity changes impacting the company’s net worth.

Financial Leverage

The financial leverage ratio oscillates between approximately 1.7 and 1.9 throughout the periods, indicating a relatively consistent capital structure with moderate reliance on debt. A subtle decrease in leverage is noticed in the mid-periods, coinciding with the stable asset levels and equity adjustments. Later periods show a mild increase back toward the upper range near 1.9. This pattern reflects some adjustments in the balance between debt and equity, consistent with the observed decline in equity without significant asset growth.

In summary, the company's financial position over the observed quarters shows stable but not expanding total assets, a declining equity base in recent years, and a correspondingly stable but slightly rising financial leverage ratio. This implies that while the company maintains a consistent asset level, it may be increasing its reliance on debt financing relative to shareholders’ equity, warranting attention to capital management strategies and risk exposure.


Interest Coverage

Medtronic PLC, interest coverage calculation (quarterly data)

Microsoft Excel
Oct 24, 2025 Jul 25, 2025 Apr 25, 2025 Jan 24, 2025 Oct 25, 2024 Jul 26, 2024 Apr 26, 2024 Jan 26, 2024 Oct 27, 2023 Jul 28, 2023 Apr 28, 2023 Jan 27, 2023 Oct 28, 2022 Jul 29, 2022 Apr 29, 2022 Jan 28, 2022 Oct 29, 2021 Jul 30, 2021 Apr 30, 2021 Jan 29, 2021 Oct 30, 2020 Jul 31, 2020
Selected Financial Data (US$ in millions)
Net income attributable to Medtronic
Add: Net income attributable to noncontrolling interest
Add: Income tax expense
Add: Interest expense, net
Earnings before interest and tax (EBIT)
Solvency Ratio
Interest coverage1
Benchmarks
Interest Coverage, Competitors2
Abbott Laboratories
Elevance Health Inc.
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).

1 Q2 2026 Calculation
Interest coverage = (EBITQ2 2026 + EBITQ1 2026 + EBITQ4 2025 + EBITQ3 2025) ÷ (Interest expenseQ2 2026 + Interest expenseQ1 2026 + Interest expenseQ4 2025 + Interest expenseQ3 2025)
= ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The analysis of the quarterly financial data reveals fluctuating patterns in earnings before interest and tax (EBIT), interest expense, and interest coverage over the reported periods.

Earnings Before Interest and Tax (EBIT)
EBIT shows considerable volatility throughout the quarters, with notable peaks and troughs. Initially, EBIT rose from 755 million US dollars to a peak of 1707 million US dollars in April 2021. Following this, there was a decline and then another increase, reaching values close to or above 1700 million US dollars in several subsequent quarters, such as January 2022, April 2022, and January 2025. However, several quarters observed significant decreases, for instance, July 2022 and April 2024, where EBIT dropped closer to or below 1100 million US dollars. Overall, while EBIT demonstrates an upward trend over time with cyclical dips, the data highlights instability and considerable variation across the quarters.
Interest Expense, Net
Interest expense remained relatively stable with mild fluctuations, generally ranging between 130 million and 210 million US dollars each quarter. There were minor increases during certain quarters, such as in April 2024 and October 2024, where interest expense peaked near 200 million US dollars. Earlier quarters included some outliers, like a spike to 470 million US dollars in October 2020, which significantly exceeds the typical range. Apart from this outlier, interest expense shows moderate variation, indicating fairly consistent borrowing costs or debt servicing expenses over time.
Interest Coverage Ratio
The interest coverage ratio, which measures the company’s ability to meet interest obligations from EBIT, manifests a variable but generally strong coverage capability. The ratio started relatively high at 6.6 and declined to a low near 3.68 in January 2021, coinciding with a low EBIT and a relatively high interest expense in the preceding quarters. After this low point, the ratio sharply improved and stabilized around values above 8 from the second half of 2021 through the most recent quarters. Peaks reaching over 10 occurred in late 2021 and early 2022. Despite some fluctuations, particularly slight declines in mid-2023 and mid-2024, the ratio remains indicative of healthy EBIT coverage for interest expenses overall.

In summary, the financial data reflects EBIT volatility with intermittent high and low quarters influencing the overall earnings performance. Interest expense levels maintain moderate consistency except for a single early outlier. Interest coverage ratios show initial weakness improving substantially thereafter, signaling that the company has enhanced its capacity to cover interest expenses comfortably, suggesting improved operational profitability and financial stability over the analyzed period.